Global Squamous Cell Carcinoma Treatment Market, By Drugs (Topical Treatment, Targeted Therapy), Treatment Type (Radiation therapy, Cryotherapy, Immunotherapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Squamous Cell Carcinoma Treatment Market Analysis and Size
The global squamous cell carcinoma treatment market is expected to witness significant growth during the forecast period. A number of factors are associated with high risks of developing squamous cell carcinoma including old age, genetic inheritance, caucasian features that includes light skin color, red or blonde hair, blue, green colored eyes, exposure to radiations, excessive use of tanning beds or UV lamps, and HIV, HPV or AIDS infection. The factors boosted the growth of squamous cell carcinoma treatment market are increase in squamous cell carcinoma cases across the world and the vulnerable aging population that would influence the demand of novel drugs for squamous cell carcinoma treatment. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global squamous cell carcinoma treatment market in the forecast period 2022-2029. The expected CAGR of global squamous cell carcinoma treatment market is tend to be around 9.50% in the mentioned forecast period. The market was valued at USD 900 million in 2021, and it would grow upto USD 1860.18 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Squamous cell carcinoma treatment is the most common form of skin cancer that devises from the squamous cells present in the skin's middle and outer layers. It is caused either by long exposure to harmful ultraviolet (UV) radiation or maybe some other idiopathic reasons. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period
Squamous Cell Carcinoma Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drugs (Topical Treatment, Targeted Therapy), Treatment Type (Radiation therapy, Cryotherapy, Immunotherapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Johnson & Johnson Private Limited (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Bausch Health Companies Inc. (Canada), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Amneal Pharmaceuticals LLC. (U.S.), Pfizer Inc (U.S.), Mylan N.V. (U.S.), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (Germany), Otsuka America Pharmaceutical, Inc (Japan), Duchesnay Inc (Canada), Kyowa Kirin Co., Ltd (Japan)
|
|
Market Opportunities
|
|
Global Squamous Cell Carcinoma Treatment Market Dynamics
Drivers
- Increase in Non-melanoma Skin Cancer
Depleting the ozone layer of the atmosphere surges the sun's penetration by harmful UV rays. Long exposure to the sun and factors such as fair complexion, exposure to chemical carcinogens such as arsenic, and genetic factors raise the risk of developing squamous cell carcinoma. All these environmental factors accelerate the rate of squamous cell carcinoma. This boost the market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global squamous cell carcinoma treatment market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
- Increased Drug Approvals
There are recent approvals from major market players that create much opportunities for the market growth. For instance, Regeneron Pharmaceuticals, Inc. is a U.S. based biopharmaceutical company that helps to treat eye diseases, allergic & inflammatory diseases, cancer, cardiovascular & metabolic diseases, infectious diseases, and rare diseases. The company recently approved Libtayo (cemiplimab-rwlc) that is shown for treating patients with squamous cell carcinoma who are unsuitable for curative surgery or curative radiation.
- Rising Healthcare Awareness
Health awareness among the population are increasing which results in the prediction of drugs boost the market growth. The innovative launches in medications for the treatment of squamous cell carcinoma are anticipated to boost the market simultaneously. Several researchers are investing in launching the drugs that benefit the market. This creates more opportunities in the market.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of skilled professionals who are unaware of the knowledge of the treatment methods for this disease could restrict the growth of the global squamous cell carcinoma treatment market during a forecast period.
- High Cost
The huge expenditure of the treatment methods surely hamper the market growth.
This global squamous cell carcinoma treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global squamous cell carcinoma treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Squamous Cell Carcinoma Treatment Market Scope
The global squamous cell carcinoma treatment market is segmented on the basis of treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drugs
- Topical Treatment
- Targeted Therapy
Treatment Type
- Radiation therapy
- Cryotherapy
- Immunotherapy
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Squamous Cell Carcinoma Treatment Market Regional Analysis/Insights
The global squamous cell carcinoma treatment market is analysed and market size insights and trends are provided by treatment type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global squamous cell carcinoma treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the rise cases of breast cancer, increased prevalence of osteoporosis, and advanced healthcare facilities.
Asia-Pacific dominates the market due to the increase government initiatives and rapidly aging population.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Squamous Cell Carcinoma Treatment Market Share Analysis
The global squamous cell carcinoma treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global squamous cell carcinoma treatment market.
Key players operating in the global squamous cell carcinoma treatment market include:
- Johnson & Johnson Private Limited (U.S.)
- Abbott (U.S.)
- AbbVie Inc. (U.S.)
- Bausch Health Companies Inc. (Canada)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Hikma Pharmaceuticals PLC (U.K.)
- Amneal Pharmaceuticals LLC. (U.S.)
- Pfizer Inc (U.S.)
- Mylan N.V. (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- GSK plc. (U.K.)
- Bayer AG (Germany)
- Otsuka America Pharmaceutical, Inc (Japan)
- Duchesnay Inc (Canada)
- Kyowa Kirin Co., Ltd (Japan)
SKU-